An Exploratory, Open-label Phase Ib Study of RNActive-Derived Cancer Vaccine and Local Radiation as Consolidation and Maintenance Treatment in Patients With Stage IV NSCLC and a Response or Stable Disease After First-line Chemotherapy or Therapy With an EGFR Tyrosine Kinase Inhibitor

Trial Profile

An Exploratory, Open-label Phase Ib Study of RNActive-Derived Cancer Vaccine and Local Radiation as Consolidation and Maintenance Treatment in Patients With Stage IV NSCLC and a Response or Stable Disease After First-line Chemotherapy or Therapy With an EGFR Tyrosine Kinase Inhibitor

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs CV 9202 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors CureVac
  • Most Recent Events

    • 04 Aug 2016 Status changed from active, no longer recruiting to discontinued.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 12 Apr 2015 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top